[In Context] Expecting exoskeletons for more than spinal cord injury
Exoskeletons that can help the paralysed to walk are available now. But they might also help patients with stroke damage, cerebral palsy, multiple sclerosis, or Parkinson's disease. So when might they be ready to take home? Adrian Burton investigates. (Source: Lancet Neurology)
Source: Lancet Neurology - February 13, 2018 Category: Neurology Authors: Adrian Burton Tags: In Context Source Type: research
[In Context] Tom Bird: one of the world's first experts in neurogenetics
Speaking to The Lancet Neurology from his home in Seattle, Tom Bird has much to be proud of in a career stretching back more than half a century. Bird set up the first neurogenetics clinic for adults in the USA at the University of Washington (Seattle, WA) in 1974, and since then has worked tirelessly to unravel the genetic secrets of many neurological diseases. (Source: Lancet Neurology)
Source: Lancet Neurology - February 5, 2018 Category: Neurology Authors: Tony Kirby Tags: In Context Source Type: research
[Articles] Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study
Mutation carriers had elevations in A β deposition, reduced glucose metabolism, and cortical thinning compared with non-carriers which preceded the expected onset of dementia. Accrual of these pathologies varied throughout the brain, suggesting differential regional and temporal vulnerabilities to Aβ, metabolic decline, and structural atrophy, which should be taken into account when using biomarkers in a clinical setting as well as designing and evaluating clinical trials. (Source: Lancet Neurology)
Source: Lancet Neurology - January 31, 2018 Category: Neurology Authors: Brian A Gordon, Tyler M Blazey, Yi Su, Amrita Hari-Raj, Aylin Dincer, Shaney Flores, Jon Christensen, Eric McDade, Guoqiao Wang, Chengjie Xiong, Nigel J Cairns, Jason Hassenstab, Daniel S Marcus, Anne M Fagan, Clifford R Jack, Russ C Hornbeck, Katrina L P Tags: Articles Source Type: research
[Comment] Capturing the Alzheimer's disease pathological cascade
Alzheimer's disease is thought to begin insidiously, when amyloid β (Aβ) aggregates into plaques in the brain while cognition is still unimpaired. After Aβ aggregation has started, it can take up to 20 years for full-blown dementia to manifest.1,2 What happens during this period is uncertain, as long-term follow-up studies have not yet been completed. Current d isease development models are based mostly on cross-sectional studies in people without dementia who have aggregated Aβ, as assessed indirectly by biomarkers in CSF or by PET scanning. (Source: Lancet Neurology)
Source: Lancet Neurology - January 31, 2018 Category: Neurology Authors: Betty M Tijms, Pieter Jelle Visser Tags: Comment Source Type: research
[Review] Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan
Improvements in the function, quality of life, and longevity of patients with Duchenne muscular dystrophy (DMD) have been achieved through a multidisciplinary approach to management across a range of health-care specialties. In part 3 of this update of the DMD care considerations, we focus on primary care, emergency management, psychosocial care, and transitions of care across the lifespan. Many primary care and emergency medicine clinicians are inexperienced at managing the complications of DMD. (Source: Lancet Neurology)
Source: Lancet Neurology - January 24, 2018 Category: Neurology Authors: David J Birnkrant, Katharine Bushby, Carla M Bann, Susan D Apkon, Angela Blackwell, Mary K Colvin, Linda Cripe, Adrienne R Herron, Annie Kennedy, Kathi Kinnett, James Naprawa, Garey Noritz, James Poysky, Natalie Street, Christina J Trout, David R Weber, L Tags: Review Source Type: research
[Review] Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management
A coordinated, multidisciplinary approach to care is essential for optimum management of the primary manifestations and secondary complications of Duchenne muscular dystrophy (DMD). Contemporary care has been shaped by the availability of more sensitive diagnostic techniques and the earlier use of therapeutic interventions, which have the potential to improve patients' duration and quality of life. In part 2 of this update of the DMD care considerations, we present the latest recommendations for respiratory, cardiac, bone health and osteoporosis, and orthopaedic and surgical management for boys and men with DMD. (Source: Lancet Neurology)
Source: Lancet Neurology - January 24, 2018 Category: Neurology Authors: David J Birnkrant, Katharine Bushby, Carla M Bann, Benjamin A Alman, Susan D Apkon, Angela Blackwell, Laura E Case, Linda Cripe, Stasia Hadjiyannakis, Aaron K Olson, Daniel W Sheehan, Julie Bolen, David R Weber, Leanne M Ward, DMD Care Considerations Work Tags: Review Source Type: research
[Review] Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management
Since the publication of the Duchenne muscular dystrophy (DMD) care considerations in 2010, multidisciplinary care of this severe, progressive neuromuscular disease has evolved. In conjunction with improved patient survival, a shift to more anticipatory diagnostic and therapeutic strategies has occurred, with a renewed focus on patient quality of life. In 2014, a steering committee of experts from a wide range of disciplines was established to update the 2010 DMD care considerations, with the goal of improving patient care. (Source: Lancet Neurology)
Source: Lancet Neurology - January 23, 2018 Category: Neurology Authors: David J Birnkrant, Katharine Bushby, Carla M Bann, Susan D Apkon, Angela Blackwell, David Brumbaugh, Laura E Case, Paula R Clemens, Stasia Hadjiyannakis, Shree Pandya, Natalie Street, Jean Tomezsko, Kathryn R Wagner, Leanne M Ward, David R Weber, DMD Care Tags: Review Source Type: research
[In Context] With no direction home
Every now and then, a show comes along and touches you in a special way with its heartfelt humanity. Girl from the North Country is one of those shows. Written and directed by Irish playwright Conor McPherson, and now transferred from the Old Vic to the Noel Coward Theatre, this play stemmed from the idea of creating a piece of work inspired by the music of American songwriter and Nobel Prize winner in literature Bob Dylan. From this inspiration, McPherson conjured a world of fragile characters ridden with longing where Dylan's songs, magistrally rearranged by Simon Hale, are instrumental to reveal the characters' unexpres...
Source: Lancet Neurology - January 22, 2018 Category: Neurology Authors: Marco De Ambrogi Tags: In Context Source Type: research
[Review] IgG4-related disease of the central and peripheral nervous systems
IgG4-related disease can involve nearly any organ system, including the central and peripheral nervous systems. The pathology findings are consistent from organ to organ, but careful clinicopathological correlation is necessary to establish the diagnosis. Many non-neurological and neurological inflammatory conditions, previously regarded as idiopathic in nature, are now recognised to fall within the spectrum of IgG4-related disease. The condition is highly treatable, but probably remains substantially under-recognised. (Source: Lancet Neurology)
Source: Lancet Neurology - January 18, 2018 Category: Neurology Authors: Mahmoud A AbdelRazek, Nagagopal Venna, John H Stone Tags: Review Source Type: research
[Articles] Prediction of late seizures after ischaemic stroke with a novel prognostic model (the SeLECT score): a multivariable prediction model development and validation study
This easily applied instrument was shown to be a good predictor of the risk of late seizures after stroke in three external validation cohorts and is freely available as a smartphone app. The SeLECT score has the potential to identify individuals at high risk of seizures and is a step towards more personalised medicine. It can inform the selection of an enriched population for antiepileptogenic treatment trials and will guide the recruitment for biomarker studies of epileptogenesis. (Source: Lancet Neurology)
Source: Lancet Neurology - January 18, 2018 Category: Neurology Authors: Marian Galovic, Nico D öhler, Barbara Erdélyi-Canavese, Ansgar Felbecker, Philip Siebel, Julian Conrad, Stefan Evers, Michael Winklehner, Tim J von Oertzen, Hans-Peter Haring, Anna Serafini, Giorgia Gregoraci, Mariarosaria Valente, Francesco Janes, Gian Tags: Articles Source Type: research
[Articles] Accelerated long-term forgetting in presymptomatic autosomal dominant Alzheimer's disease: a cross-sectional study
Accelerated long-term forgetting is an early presymptomatic feature of autosomal dominant Alzheimer's disease, which appears to pre-date other amnestic deficits and might underpin subjective memory complaints in Alzheimer's disease. Accelerated long-term forgetting testing might be useful in presymptomatic Alzheimer's disease trials. (Source: Lancet Neurology)
Source: Lancet Neurology - January 18, 2018 Category: Neurology Authors: Philip S J Weston, Jennifer M Nicholas, Susie M D Henley, Yuying Liang, Kirsty Macpherson, Elizabeth Donnachie, Jonathan M Schott, Martin N Rossor, Sebastian J Crutch, Christopher R Butler, Adam Z Zeman, Nick C Fox Tags: Articles Source Type: research
[In Context] Evolving diagnostic criteria for multiple sclerosis
Multiple sclerosis —MS. These two letters can change lives in an instant for young people starting out in their careers and family life. MS is hard to define, hard to treat, and hard to take. Yet over the past two decades, treatment has changed radically, from none to over a dozen disease modifying drugs that can re duce attack rate and mitigate disability. The 2017 revisions of the multiple sclerosis diagnostic criteria1 provide an opportunity for reflection. (Source: Lancet Neurology)
Source: Lancet Neurology - January 18, 2018 Category: Neurology Authors: Jeremy Chataway Tags: In Context Source Type: research
[In Context] Peter Turkeltaub
Peter Turkeltaub is an Associate Professor of Neurology and Rehabilitation Medicine at Georgetown University Medical Center and Director of the Aphasia Clinic at MedStar National Rehabilitation Hospital (Washington, DC, USA). He currently studies the neural basis of speech, language and related functions, plasticity of language networks after injury, and new neuromodulatory treatments for aphasia. (Source: Lancet Neurology)
Source: Lancet Neurology - January 18, 2018 Category: Neurology Tags: In Context Source Type: research
